Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets

Protein Science

Volumn 24, Issue 4, 2015, Pages 446-463

  Clinton, Tracy R ^a   Weinstock, Matthew T ^a,d   Jacobsen, Michael T ^a   Szabo Fresnais, Nicolas ^a   Pandya, Maya J ^a   Whitby, Frank G ^a   Herbert, Andrew S ^b   Prugar, Laura I ^b   McKinnon, Rena ^c   Hill, Christopher P ^a   Welch, Brett D ^c   Dye, John M ^b   Eckert, Debra M ^a   Kay, Michael S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c NAVIGEN INC   (United States)

^d Synthetic Genomics Inc   (United States)

Author keywords

designed coiled coil; ebolavirus; ebolavirus GP2; filovirus entry; mirror image phage display; N trimer; phage display; prehairpin intermediate

Indexed keywords

ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; CHEMISTRY; DRUG DELIVERY SYSTEM; EBOLAVIRUS; GENETICS; METABOLISM; MOLECULAR GENETICS; MOLECULAR MODEL; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; DRUG DELIVERY SYSTEMS; EBOLAVIRUS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS;

EID: 84956659354     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2578     Document Type: Article

References (77)

1. Sanchez A, Kahn AS, Zaki SR, Nabel GJ, Ksiazek TG, Peters CJ, (2001) Fields virology. Philadelphia: Lippincott, Williams and Wilkins.
2. Centers for Disease Control and Prevention (2014) Chronology of Ebola hemorrhagic fever outbreaks. http://www.cdc.gov/vhf/ebola/resources/outbreak-table.html.
3. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keita S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traore A, Kolie M, Malano ER, Heleze E, Bocquin A, Mely S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Gunther S, (2014) Emergence of Zaire Ebola virus disease in Guinea-Preliminary report. New Engl J Med 371: 1418-1425.
4. Bossi P, Garin D, Guihot A, Gay F, Crance JM, Debord T, Autran B, Bricaire F, (2006) Bioterrorism: Management of major biological agents. Cell Mol Life Sci 63: 2196-2212.
5. White JM, Delos SE, Brecher M, Schornberg K, (2008) Structures and mechanisms of viral membrane fusion proteins: Multiple variations on a common theme. Crit Rev Biochem Mol Biol 43: 189-219.
6. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD, (1998) Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 95: 5762-5767.
7. Volchkov VE, Volchkova VA, Stroher U, Becker S, Dolnik O, Cieplik M, Garten W, Klenk HD, Feldmann H, (2000) Proteolytic processing of Marburg virus glycoprotein. Virology 268: 1-6.
8. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR, (2011) Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343.
9. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM, (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308: 1643-1645.
10. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J, (2011) Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477: 344-348.
11. Misasi J, Chandran K, Yang JY, Considine B, Filone CM, Cote M, Sullivan N, Fabozzi G, Hensley L, Cunningham J, (2012) Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol 86: 3284-3292.
12. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J, (2006) Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 80: 4174-4178.
13. Eckert DM, Kim PS, (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810.
14. Lee JE, Saphire EO, (2009) Ebolavirus glycoprotein structure and mechanism of entry. Future Virol 4: 621-635.
15. White JM, Schornberg KL, (2012) A new player in the puzzle of filovirus entry. Nat Rev Microbiol 10: 317-322.
16. Harrison JS, Higgins CD, Chandran K, Lai JR, (2011) Designed protein mimics of the Ebola virus glycoprotein GP2 alpha-helical bundle: Stability and pH effects. Protein Sci 20: 1587-1596.
17. Root MJ, Steger HK, (2004) HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 10: 1805-1825.
18. Francis JN, Redman JS, Eckert DM, Kay MS, (2012) Design of a modular tetrameric scaffold for the synthesis of membrane-localized D -peptide inhibitors of HIV-1 entry. Bioconjug Chem 23: 1252-1258.
19. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD, (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109: 5034-5039.
20. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I, (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study. Lancet 375: 1896-1905.
21. Marzi A, Feldmann H, Geisbert TW, Falzarano D, (2011) Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef S1(4).
22. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP, (2012) Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4: 138ra181.
23. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S, (2010) Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16: 991-994.
24. Eckert DM, Kim PS, (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 98: 11187-11192.
25. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS, (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99: 103-115.
26. Eckert DM, Malashkevich VN, Kim PS, (1998) Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J Mol Biol 284: 859-865.
27. Malashkevich VN, Schneider BJ, McNally ML, Milhollen MA, Pang JX, Kim PS, (1999) Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci USA 96: 2662-2667.
28. Weissenhorn W, Carfi A, Lee KH, Skehel JJ, Wiley DC, (1998) Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 2: 605-616.
29. Welch BD, VanDemark AP, Heroux A, Hill CP, Kay MS, (2007) Potent D-Peptide Inhibitors of HIV-1 Entry. Proc Natl Acad Sci USA 104: 16828-16833.
30. Chan DC, Fass D, Berger JM, Kim PS, (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
31. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC, (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
32. Welch BD, Francis JN, Redman JS, Paul S, Weinstock MT, Reeves JD, Lie YS, Whitby FG, Eckert DM, Hill CP, Root MJ, Kay MS, (2010) Design of a potent D -peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol 84: 11235-11244.
33. Salerno WJ, Seaver SM, Armstrong BR, Radhakrishnan I, (2004) MONSTER: Inferring non-covalent interactions in macromolecular structures from atomic coordinate data. Nucleic Acids Res 32: W566-W568.
34. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, Lu M, An Z, Ingallinella P, Finotto M, Mattu M, Finnefrock AC, Bramhill D, Cook J, Eckert DM, Hampton R, Patel M, Jarantow S, Joyce J, Ciliberto G, Cortese R, Lu P, Strohl W, Schleif W, McElhaugh M, Lane S, Lloyd C, Lowe D, Osbourn J, Vaughan T, Emini E, Barbato G, Kim PS, Hazuda DJ, Shiver JW, Pessi A, (2005) A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci USA 102: 14759-14764.
35. Montgomery DL, Wang YJ, Hrin R, Luftig M, Su B, Miller MD, Wang F, Haytko P, Huang L, Vitelli S, Condra J, Liu X, Hampton R, Carfi A, Pessi A, Bianchi E, Joyce J, Lloyd C, Geleziunas R, Bramhill D, King VM, Finnefrock AC, Strohl W, An Z, (2009) Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs 1: 462-474.
36. Schumacher TN, Mayr LM, Minor DL, Jr., Milhollen MA, Burgess MW, Kim PS, (1996) Identification of D -peptide ligands through mirror-image phage display. Science 271: 1854-1857.
37. Weinstock MT, Francis JN, Redman JS, Kay MS, (2012) Protease-resistant peptide design-empowering nature's fragile warriors against HIV. Biopolymers 98: 431-442.
38. Zawadzke LE, Berg JM, (1992) A racemic protein. J Am Chem Soc 114: 4002-4003.
39. Dintzis HM, Symer DE, Dintzis RZ, Zawadzke LE, Berg JM, (1993) A comparison of the immunogenicity of a pair of enantiomeric proteins. Proteins 16: 306-308.
40. Noren KA, Noren CJ, (2001) Construction of high-complexity combinatorial phage display peptide libraries. Methods 23: 169-178.
41. Weinstock MT, Jacobsen MT, Kay MS, (2014) Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity. Proc Natl Acad Sci USA 111: 11679-11684.
42. Hackenberger CP, Schwarzer D, (2008) Chemoselective ligation and modification strategies for peptides and proteins. Angew Chem Int Ed Engl 47: 10030-10074.
43. Blanco-Canosa JB, Dawson PE, (2008) An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation. Angew Chem Int Edit 47: 6851-6855.
44. Wan Q, Danishefsky SJ, (2007) Free-radical-based, specific desulfurization of cysteine: A powerful advance in the synthesis of polypeptides and glycopolypeptides. Angew Chem Int Ed Engl 46: 9248-9252.
45. Joshi SB, Dutch RE, Lamb RA, (1998) A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology 248: 20-34.
46. Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK, (2009) Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. Antiviral Res 81: 82-87.
47. Wild C, Greenwell T, Matthews T, (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 9: 1051-1053.
48. Watanabe S, Takada A, Watanabe T, Ito H, Kida H, Kawaoka Y, (2000) Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol 74: 10194-10201.
49. Higgins CD, Koellhoffer JF, Chandran K, Lai JR, (2013) C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: Effects of conjugation to cholesterol and side chain-side chain crosslinking. Bioorgan Med Chem Lett 23: 5356-5360.
50. Miller EH, Harrison JS, Radoshitzky SR, Higgins CD, Chi X, Dong L, Kuhn JH, Bavari S, Lai JR, Chandran K, (2011) Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem 286: 15854-15861.
51. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL, (2011) Identification of a small-molecule entry inhibitor for filoviruses. J Virol 85: 3106-3119.
52. Roffey R, Tegnell A, Elgh F, (2002) Biological warfare in a historical perspective. Clin Microbiol Infect 8: 450-454.
53. Chen BK, Saksela K, Andino R, Baltimore D, (1994) Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol 68: 654-660.
54. Kuhn JH, Radoshitzky SR, Guth AC, Warfield KL, Li W, Vincent MJ, Towner JS, Nichol ST, Bavari S, Choe H, Aman MJ, Farzan M, (2006) Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 281: 15951-15958.
55. Connor RI, Chen BK, Choe S, Landau NR, (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206: 935-944.
56. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR, (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69: 6705-6711.
57. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR, (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
58. Landau NR, Littman DR, (1992) Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 66: 5110-5113.
59. Hamburger AE, Kim S, Welch BD, Kay MS, (2005) Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280: 12567-12572.
60. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST, (1996) The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA 93: 3602-3607.
61. Studier FW, (2005) Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 41: 207-234.
62. Blommel PG, Fox BG, (2007) A combined approach to improving large-scale production of tobacco etch virus protease. Protein Expr Purif 55: 53-68.
63. van den Berg S, Lofdahl PA, Hard T, Berglund H, (2006) Improved solubility of TEV protease by directed evolution. J Biotechnol 121: 291-298.
64. Blanco-Canosa JB, Dawson PE, (2008) An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation. Angew Chem Int Ed Engl 47: 6851-6855.
65. Edelhoch H, (1967) Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6: 1948-1954.
66. Rohl CA, Baldwin RL, (1997) Comparison of NH exchange and circular dichroism as techniques for measuring the parameters of the helix-coil transition in peptides. Biochemistry 36: 8435-8442.
67. Cole JL, (2004) Analysis of heterogeneous interactions. Methods Enzymol 384: 212-232.
68. Laue T, Shah B, Ridgeway T, Pelletier S,. Computer-aided interpretation of analytical sedimentation data for proteins. (1992) Analytical ultrancentrifugation in biochemistry and polymer science. Roy Soc Chem pp 90-125.
69. Wohlfarth C,. Partial specific volume of poly(ethylene glycol). In:, Lechner MD, Arndt KF, Eds. (2010) Polymer solutions. Berlin: Springer.
70. O'Shannessy DJ, Brigham-Burke M, Soneson KK, Hensley P, Brooks I, (1993) Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: Use of nonlinear least squares analysis methods. Anal Biochem 212: 457-468.
71. Otwinowski Z, Minor W,. Processing of X-ray diffraction data collected in oscillation mode. In:, Carter JCW, Sweet RM, Eds. (1997) Methods in enzymology. San Diego: Academic Press, pp 307-326.
72. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ, (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
73. Emsley P, Cowtan K, (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D 60: 2126-2132.
74. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH, (2010) PHENIX: A comprehensive python-based system for macromolecular structure solution. Acta Crystallogr D 66: 213-221.
75. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC, (2010) MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D 66: 12-21.
76. Jeffers SA, Sanders DA, Sanchez A, (2002) Covalent modifications of the ebola virus glycoprotein. J Virol 76: 12463-12472.
77. Henikoff S, Henikoff JG, (1992) Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA 89: 10915-10919.